A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?

Mei Liu1 · Yu Zhang2 · Yu Guo2 · Jian Gao2 · Wenhai Huang3 · Xiaowu Dong2

Received: 5 February 2021 / Accepted: 4 April 2021 / Published online: 13 April 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract
Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have become a “game-changer” in the cancer treatment. However, none of the small molecular inhibitors has been approved yet. To explore the advantages and disadvantages of various scaffolds, different biological evaluations were performed on the three selected small inhibitors, namely Incyte-001, Incyte-011, and BMS-1001. In the HTRF assay, BMS-1001 showed the best binding activity for PD-L1 (IC50 = 0.9 nM) while Incyte-011 (IC50 = 5.293 nM) was twice more potent than the Incyte-001 (IC50 = 11 nM). Also, only Incyte-011 increased the IFN-γ production. Notably, the Incyte-001 exhibited the highest cytotoxicity (EC50 = 1.635 μM). Interestingly, Incyte-001 (injected intravenously 2 mg/kg) also displayed good blood-brain barrier permeability and reached a high concentration in the brain tissue. Finally, molecular docking and modeling studies suggested that the compounds bind in a pocket at the interface of two PD-L1 monomers. Overall, our work shows that PD-1/PD-L1 small molecular inhibitors have different biological characteristics depending on their unique skeletons, which can be further improved to better their clinical application.

Keywords Cancer immunotherapy · PD-1/PD-L1 · Small molecular inhibitors · Immune checkpoint inhibitors

Introduction
Immunotherapy is an emerging approach for oncological treatment [1]. Especially, the immune checkpoint inhibitors (ICIs) that target the PD-1/PD-L1 pathway get a lot of attention and have shown great improvement in the treatment of several tumors [2–4].

Programmed cell death 1 (PD-1), an important immunosuppressive molecule, is expressed on various immune cells, including T cells, B cells, tumor-associated macrophages (TAMs), and natural killer cells (NK cells) [5, 6]. In the tumor cells, overexpression of PD-L1 induces the PD-1/PD-L1 pathway which inhibits T cell mediated anti-tumor
immune response, and thereby facilitate the survival of tumor cells [7, 8]. Therefore, the ICIs have become one of the most promising agents in cancer therapy.

Notably, the monoclonal antibodies (mAbs) of PD-1/PD-L1 inhibitors have shown significant clinical effectiveness in various tumors including melanoma, lung cancer, Hodgkin lymphoma, urothelial carcinoma, bladder cancer, colorectal cancer, renal cell carcinoma, and glioblastoma [9–12]. And these monoclonal antibodies showing their advantages, also have several disadvantages such as lack of oral bioavailability, prolonged half-life, poor permeability, immune-related adverse effects (irAEs), and relatively lower clinical response in brain tumors [13–15]. However, these shortcomings can be overcome by developing small molecular inhibitors.

Recently, a series of small molecular inhibitors, including macrocyclic peptides, peptide mimetics, and non-peptide small molecular inhibitors, have been discovered for improvement of treatment [16–19]. Among them, small molecules discovered by Bristol-Myers Squibb (BMS) exhibit activity in the nanomolar range. Their skeletons have a biphenyl group connected to a substituted aromatic ring by a benzyl ether bond. Shortly, other companies including Incyte, Gilead, and etc., also disclosed similar compounds, including a series of C2 symmetrical skeleton compounds. Interestingly, through the HTRF (Homogeneous Time-Resolved Fluorescence) assay and cell-based co-culture PD-L1 signaling assay, C2 symmetrical skeleton compounds with dimer-structure are revealed to be more effective than the monomers [20]. However, the reason remains unknown. And their toxicity and druggability still need to be evaluated. Furthermore, unlike monoclonal antibodies, these small molecular inhibitors may have the potent for crossing the blood-brain barrier (BBB) and for the treatment of central neural system (CNS) tumors. Therefore, it is vital to evaluate their blood-brain barrier (BBB) penetrability and distribution in the brain.

Results and discussion

Chemistry

The synthesis of Incyte-001 is shown in Scheme 2 [21]. Starting with commercially available 2-amino-6-bromobenzonitrile 1, Suzuki coupling reaction with phenyl-boronic acid produced biphenyl-nitrile product 2. The resulting compound was treated with O-(7-Aza-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and coupled with 5-bromopicolinic acid 3 to provide bromopicolinamide intermediate 4. Then, this was reacted with pinacol vinyl boronate in the presence of palladium catalyst to obtain vinylpicolinamide compound 5. Next, using K2OsO4/NaIO4, classical oxidative cleavage of double bond in the compound 5 resulted in formylpicolinamide 6. Lastly, reductive amination with ethanolamine produced the final product Incyte-001.
The synthesis of Incyte-011 is shown in Scheme 3 [22]. Pinacol boronation of commercially available 3-bromo-2-methylaniline 7 with bis(pinacolato)diboron under standard condition produced arylboronate 8 in good yield, which was subsequently Suzuki coupled with 3-bromo-2-chloroaniline 9. The resulting biphenyl-diamine intermediate 10 was treated with HATU and coupled with 5-bromopicolinic acid 3 to obtain compound 11 with 58% yield. Compound 11, reacted with pinacol vinylboronate and catalyzed with tetrakis(triphenylphosphine) palladium, produced dienes compound 12 in good yield. Then, the oxidative cleavage of the dienes intermediate 12 with K$_2$OsO$_4$/NaIO$_4$ provided an aldehyde intermediate 13 in mild yield. Finally, reductive amination with ethanolamine yielded the desired product Incyte-011.

The synthesis of BMS-1001 is shown in Scheme 4 [23]. Starting from commercially available 3-bromo-2-methylbenzoic acid 14, reduction reaction with BH$_3$-THF produced (3-bromo-2-methylphenyl)methanol product 15, which was coupled with (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)boronic acid to obtain intermediate 16. Then, the intermediate 16 was reacted with 2,4-dihydroxy-5-methylbenzaldehyde (Mitsunobu Reaction) to obtain the compound 17 which upon reductive amination with Serine produced the final product BMS-1001.
Homogeneous time resolved fluorescence (HTRF)

The PD-1/PD-L1 blocking abilities of the compounds were estimated using the HTRF assay. We found that both compounds from Incyte Inc. showed great activities within the nanomolar range. The IC_{50} values of the compound 001 and 011 were 11 nM and 5.293 nM, respectively. This suggested that compound 011 is almost twice potent than the compound 001. And the result is consistent with a previous report [20]. More interestingly, BMS-1001 displayed the best result with an IC_{50} value of 0.9 nM in our study, which is worth exploring furthermore (Fig. 1).

In vitro estimation of IFN-γ secretion levels

Many studies showed that blockade of the PD-1/PD-L1 interaction could re-activate T cell function such as the secretion of IFN-γ, which suggested the inhibition of immune escape in the tumor cells [24]. Thus, an in vitro T cell co-culture assay was performed to assess the T cell activation effect of selected compounds (Fig. 2). Treatment with Incyte-011 increased the production of IFN-γ in a dose-dependent manner. And the level of IFN-γ had reached to 200 pg/mL at the maximum dose (1 μM) of Incyte-011. However, the compound Incyte-001 and BMS-1001 had failed to affect IFN-γ production significantly. Obviously, Incyte-011 was more potent in blocking the PD-1/PD-L1 interactions, compared with the monomer molecular Incyte-001. For BMS-1001, the different chemical skeleton could be the reason for such an outcome.

The PD-1/PD-L1 signaling pathway can restrict the formation of immune response through a variety of ways. By inhibiting the proliferation, activation and secretion of effector T cells, the pathogen can infect the body for a long time. This tolerance state can be broken by blocking PD-1/PD-L1, which is conducive to clearing the pathogen. To date, blocking the PD-1/PD-L1 signaling pathway has been shown to be effective against LCMV, HBV, HCV and HIV infection [25]. The above PD-L1 small molecule inhibitors with significant IFN-γ secretion stimulating effect are also expected to play a role in infectious diseases.

Evaluation of cytotoxicity

To evaluate the cytotoxicity of the compounds, the survival assay was performed in A549 tumor cells. Up to 10 μM, Incyte-011 and BMS-1001 exhibited no significant cytotoxicity. However, at 10 μM, Incyte-001 decreased the cell survival rate to 70%, showing more obvious cytotoxicity than the other two compounds. The EC_{50} value of Incyte-001 was 1.635 μM (Fig. 3).

Brain and blood distribution of compounds in mice

As described above, Incyte-001, Incyte-011, and BMS-1001 showed promising PD-1/PD-L1 blockade in vitro. Next, the pharmacokinetic (PK) properties and blood-brain barrier (BBB) permeability of the three compounds were assessed. The corresponding distribution parameters are

![Scheme 4](image)

Reagents and conditions: (a) BH$_3$-THF, THF; (b) XPhos Pd G2, K$_3$PO$_4$, THF; (c) DIAD, PPh$_3$, THF; (d) Cs$_2$CO$_3$, DMF; (e) NaBH$_3$CN, HAc, DMF
summarized in Fig. 4. After iv administration (2 mg/kg, \( n = 3 \)), BMS-1001 showed a plasma \( C_{\text{max}} \) of 5600 ng/mL at around 0.08 h, indicating a moderate systematic exposure. However, the immeasurable concentration in brain showed BMS-1001 had no ability to cross the BBB. It seems that the amino acid chain of BMS-1001 led to a poor PK profile and decreased its concentration by enhancing metabolism in the body. For Incyte-011, the plasma \( C_{\text{max}} \) values was nearly 400 ng/mL, which was higher than the brain concentration. This suggested that Incyte-011 had poor pharmacokinetic properties. Interestingly, though the plasma \( C_{\text{max}} \) of Incyte-001 was low, it exhibited the highest \( C_{\text{max}} \) value of 4000 ng/mL in the brain compared to the other two compounds. This suggested that Incyte-001 can effectively cross the BBB and therefore it may be clinically used against CNS cancer.
Molecular binding modeling between PD-L1 and compounds

To examine the binding ability between PD-L1 and respective small molecules, we performed 3 ns molecular dynamic (MD) simulations of PD-L1 bound compound complexes such as PD-L1/Incyte-001, PD-L1/Incyte-011, and PD-L1/BMS-1001. The root mean square deviation (RMSD) plot of the complexes (Figs. 5A, 6A, and 7A) revealed that PD-L1 protein reached the equilibrium after 3 ns MD simulation, having fluctuation of ~1 Å or 2 Å, respectively.

To investigate the amino acids involved in binding, the MM/GBSA decomposition protocol in AmberTools was used to decompose the Gibbs free energy (Figs. 5B, 6B, and 7B). We found that the residues Tyr56, Gln66, Met115, Ala121, Asp122, Tyr123, and Lys124 made favorable binding contributions between PD-L1 and Incyte-001 (or Incyte-011, BMS-1001). Importantly, the Lys124 and Glu58 provided a positive energy for the binding of PD-L1 and Incyte-011 (or BMS-1001), explaining the worse binding of Incyte-001. Besides, PD-L1/Incyte-011 and PD-L1/BMS-1001 complexes exhibited lower binding free energy (−70.4386 and −76.3274 kcal/mol, respectively) than the PD-L1/Incyte-001 (−55.1401 kcal/mol), suggesting stronger binding in the latter.

Furthermore, molecular docking and dynamic simulation were performed to compare the different conformations and interactions between PD-L1 and the three compounds, as reported previously [26]. Incyte-001, Incyte-011, and BMS-1001 bind in the pocket at the interface of two PD-L1 monomers (Figs. 5C, 6C, and 7C). The binding pocket is formed by several key residues including aGln66, aMet105, aAla121, aAsp122 bTyr56, bMet115, and bAsp122 (Fig. 5D). Also, the exposed benzene ring of the biphenyl group makes a π-π interaction and a π-sigma interaction with bTyr56 and aAsp122, respectively. Besides, the methyl phenyl ring forms π-alkyl interactions with bMet115 and aAla121. The pyridine ring generates π-π interactions with aTyr56 a n db T y r 5 6a n d π-alkyl interactions with aAsp122 and bAsp122, respectively. The pyridine group is involved in π-π interactions with aTyr56 and bTyr56 and π-anion interactions with aAsp122 and bAsp122, respectively. The ethanalamine group forms hydrogen bonds with aArg125, aAsp61, and bAsp122. Figure 7D depicts the binding site composed of aGln66,
aMet115, aAla121, aAsp122, aTyr123, aLys124, aArg125, bIle54, bGln66, bVal68, bMet115, and bAla121 residues. The interactions between PD-L1 and the other two compounds were almost similar. Interestingly, in addition to these, the benzonitrile portion of the pocket interacts with aArg113, aTyr123, aArg125, and bAsn63. Especially, the p-π interaction with the aArg125 may be the reason for increased potency.

Brieﬂy, this part of the work offers a structural insight to explain the difference in the binding activity of monomers, dimers, and the different chemical skeleton compound with PD-L1. Interestingly, the binding type and free energy of BMS-1001 can strongly support the best activity of inhibition for PD-1/PD-L1.

Conclusion

The immune checkpoint proteins PD-1/PD-L1 are the key proteins affecting the T cell function, which also play a crucial role for tumor immunotherapy. We employed a series of biological tests to estimate the inhibitory activities of the three PD-L1 inhibitors: Incyte-001, Incyte-011, and BMS-1001. In the HTRF assay, all three compounds showed great efficacies and inhibited PD-1/PD-L1 interactions in the nanomolar range, in which BMS-1001 exhibited the highest activity (IC50 = 0.09 nM). And the dimer Incyte-011 (IC50 = 5.293 nM) is two-fold more potent than the monomer Incyte-001 (IC50 = 11 nM), which is consistent with the previous report [20]. Subsequent molecular docking indicated that additional interactions of BMS-1001, such as a hydrogen bond with the aArg125, may account for this result.

Inhibition of PD-1/PD-L1 causes the activation of T cell function such as the production of IFN-γ. Therefore, an IFN-γ production assay was performed in our study. We found only Incyte-011 (1 μM) increased the level of IFN-γ dose-dependently, with a value of 200 pg/mL at 1 μM (the maximum dose). And in the cytotoxicity assay, Incyte-001 displayed the highest cytotoxicity (EC50 = 1.635 μM) against the A549 cells comparing with other two compounds. The results suggested that the dimer Incyte-011 has more anti-tumor activity and less cytotoxicity than the monomer molecular Incyte-001. PD-L1 small molecule inhibitors with more significant IFN-γ secretion stimulating effect are also expected to play a role in infectious diseases.

For exploring the potent of CNS tumors treatment, we assessed the pharmacokinetic (PK) properties and blood-
brain barrier (BBB) permeability of the three compounds. In our study, Incyte-001 reached a C_{max} of 4000 ng/mL in the brain and a C_{max} < 1000 ng/mL in the blood, while Incyte-011 and BMS-1001 both had lower C_{max} in the brain and higher C_{max} in the plasma, suggesting that the monomer molecular Incyte-001 has a good BBB permeability and its concentration in brain is higher. This could be related to better endocytosis [27]; however, it demands further validation. Besides, having a lipophilic structure may help the monomers to easily penetrate the BBB.

Overall, compared with the monomers (Incyte-001), the skeleton of the dimers (Incyte-011) offers high inhibitory activity which suggests that a dimeric structure of BMS-1001 may have even better efficacy. Interestingly, only Incyte-011 increased the IFN-γ production obviously. And Incyte-001, which is inferior to Incyte-011 and BMS-1001 in the above aspects, had a good BBB permeability. Our work has suggested that the dimeric structure of small-molecule PD-L1 inhibitors have higher inhibitory activity and Incyte-001 may have great clinical potential against CNS tumors, which set the basis for further improvement during the drug design for different tumor treatment.

**Experimental**

**Chemistry**

**General chemistry**

All reagents and solvents were obtained directly from the suppliers and were used without further purification. The 1H NMR spectra were recorded using a Bruker AVANCE III spectrometer in the CDCl₃ and DMSO-d₆ solution, with tetramethylsilane (TMS) as the internal standard. Chemical shift values are reported in ppm. The three compounds were synthesized according to the corresponding patents (WO2017106634A1, WO2018119221A1, WO2015160641A2) and the procedures are available in the supporting information.

**Homogeneous time resolved fluorescence (HTRF)**

The compounds were sequentially diluted following a concentration gradient. In a 96-well plate, 2 μL of the target compounds dilution was mixed with 4 μL of Tag 1-PD-L1 protein, and 4 μL of Tag 2- PD-1 protein, successively.
The mixtures were incubated for 15 min at room temperature (RT). Then the mixture of 10 μL anti-Tag1-Eu3+ and anti-Tag2-XL665 were added, and the plate was sealed to incubate for 2 h at RT in the dark. Finally, the fluorescence signal was detected at 665 nm and 620 nm. The ELISA data and IC50 values were calculated using Graphpad 7.0 software.

**In vitro estimation of IFN-γ production**

The 293T-OS8-hPDL1 cells were treated with Mitomycin C for 1.5 h and washed with PBS thrice. The cells (50,000 cells/well) were added to a 96-well plate. After 2 h, the cells were treated with different concentrations of the respective compounds (100 μL hPD-L1 and 1 μL compounds). After another 4 h, the CD3 + T cells were extracted, counted, and added to the 96-well plates. Then, the compounds were added and co-cultured at 37 °C. After 36 h, the supernatants were collected to estimate the levels of IFN-γ. The result was treated with Graphpad software and the statistical analysis was made by t test.

**In vitro cell-proliferation assay**

The cytotoxicity was detected with the CCK8 assay. The A549 cells were cultured in 96-well plates for 24 h. The compounds were sequentially diluted and was mixed with 0.1% DMSO in total 100 μL of medium. Then the solutions were added and co-cultured for 2 days. The 10 μL solution of CCK8 was added and co-cultured for 4 h. Then the fluorescence signal at 450 nm was tested by a microplate reader and the EC50 values were calculated using Graphpad 7.0 software.

**In vivo the brain and plasma distribution of compounds**

All animal experiments were performed following the guidelines of Zhejiang University Laboratory Animal Center. The BALB/c male mice were obtained from the Zhejiang Academy of Medical Sciences. The mice venous blood (100 μL) and brain tissue (100 μL) samples were collected at 0, 0.083, 0.25, 0.5, 1, 2, 4, and 8 h after intravenous injection of the test compounds. The plasma and brain tissue homogenates were obtained by centrifugation and stored at −20 °C till further use.

**Molecular docking**

The crystal structure (PDB ID: 5NIU) was obtained from http://www.rcsb.org/ and treated using Schrödinger Procedures such as residual repair, hydrogen optimization, water removal, and energy minimization were performed with Protein Preparation Wizard of Schrödinger. The LigPrep module with OPLS3e force field was used to ionize and minimize the ligands. The preprocessed proteins and ligands were docked in the Ligand Docking module.

**Molecular dynamics (MD) simulation**

The molecular dynamics (MD) simulations were carried out using AmberTools. First, the system was solvated, neutralized, and relaxed to avoid possible space collision. Each part was then heated and maintained at 300 K with a time step of 2 fs using long-distance static electricity. The cut-off value was adjusted to 8.0 Å to deal with space interaction. Each part was subjected to a 3 ns MD simulation.

**Acknowledgements** This research acknowledges the support of the Natural Science Foundation of Zhejiang Province (LQ19H090013).

**Compliance with ethical standards**

Conflict of interest The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Berndt JD, Gough NR. Signaling breakthroughs of the year. Sci Signal. 2013;2014:307. https://doi.org/10.1126/scisignal.aam5681
2. Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng ZP, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. 2017;23:6165–77. https://doi.org/10.1158/1078-0432.Ccr-16-2677
3. Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017, 24. https://doi.org/10.1186/s12929-017-0329-9.
4. Salmaninejad A, Valilou SF, Shabagh AG, Aslani S, Alamdani M, Pasdar A, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824–37. https://doi.org/10.1002/jcp.28358
5. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. En-gagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34. https://doi.org/10.1084/jem.192.7.1027
6. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765–72. https://doi.org/10.1093/intimm/8.5.765
7. Dong HD, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. https://doi.org/10.1038/nm730
8. Flies DB, Sandler BJ, Szoln M, Chen L, Blockade of the B7-H1/ PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84:409–21.
9. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications.
10. Yan Y, Zhang L, Zuo Y, Qian H, Liu C. Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors. Arch Immunol Ther Exp (Warsz). 2020;68:36. https://doi.org/10.1007/s00005-020-00601-6

11. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Disc. 2016;15:235–47. https://doi.org/10.1038/nrd.2015.35

12. Lin X, Lu X, Luo G, Xiang H. Progress in PD-1/PD-L1 pathway inhibitors: from biomacromolecules to small molecules. Eur J Med Chem. 2020;186:111876. https://doi.org/10.1016/j.ejmech.2019.111876.

13. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76-83. https://doi.org/10.1038/EdBook_AM.2015.35.76

14. Tan SG, Zhang CWH, Gao GF. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Tar. 2016;1. https://doi.org/10.1038/s41401-020-0366-x

15. Zhao JF, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:1022–1022. https://doi.org/10.1038/s41591-019-0449-8. (vol 25, pg 462, 2019)

16. Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Blaszkiewicz U, et al. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Molecules. 2019;24. https://doi.org/10.3390/molecules24112071

17. Wang T, Wu X, Guo C; Zhang K, Xu J, Li Z, et al. Development of inhibitors of the programmed cell death-1 programmed cell death-ligand 1 signaling pathway. J Med Chem. 2019;62:1715–30. https://doi.org/10.1021/acs.jmedchem.8b00990

18. Chen T, Li Q, Liu Z, Chen Y, Feng F, Sun H. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy? Eur J Med Chem. 2019;161:378–98. https://doi.org/10.1016/j.ejmech.2018.10.044

19. Wu Q, Jiang L, Li SC, He QJ, Yang B, Cao J. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharm Sin. 2021;42:1–9. https://doi.org/10.1038/s41401-020-0366-x

20. Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, et al. Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1 programmed death-ligand 1 protein-protein interaction. J Med Chem. 2019;62:7250–63. https://doi.org/10.1021/acs.jmedchem.9b00795

21. Wu L, Yu Z, Zhang F, Yao W. N-Phenyl-pyridine-2-carboxamide derivatives and their use as Pd-1/Pd-L1 Protein/protein interaction modulators. WO2017106634A1. 2017 https://worldwide.espacenet.com/patent/search/family/058191548/publication/WO2017106634A1?q=WO2017106634A1

22. Wu L, Yu Z, Zhang F, Yao W. Pyridine derivatives as immunomodulators. WO2018119221A1. 2018 https://worldwide.espacenet.com/patent/search/family/061148470/publication/WO2018119221A1?q=WO2018119221A1

23. Chupak LS, Ding M, Martin SW, Zheng X, Hewawasam P, Connolly TP, et al. Compounds useful as immunomodulators. WO2015160641A2. 2015 https://worldwide.espacenet.com/patent/search/family/054264532/publication/WO2015160641A2?q=WO2015160641A2

24. Qian JW, Wang C, Wang B, Yang J, Wang YD, Luo FF, et al. The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflamm. 2018;15. https://doi.org/10.1186/s12974-018-1330-2

25. Tapia Rico G, Chan MM, Loo KF. The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): a review of the available evidence. Cancer Treat Rev. 2020;86:102011. https://doi.org/10.1016/j.ctrv.2020.102011

26. Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7:30323–35. https://doi.org/10.18632/oncotarget.8730

27. Villaseor R, Lampe J, Schwaninger M, Collin L. Intracellular transport and regulation of transcytosis across the blood–brain barrier. Cell Mol Life Sci. 2019;76:6.